Prediction of disease progression in patients with COVID-19 by artificial intelligence assisted lesion quantification.

Journal: Scientific reports
Published Date:

Abstract

To investigate the value of artificial intelligence (AI) assisted quantification on initial chest CT for prediction of disease progression and clinical outcome in patients with coronavirus disease 2019 (COVID-19). Patients with confirmed COVID-19 infection and initially of non-severe type were retrospectively included. The initial CT scan on admission was used for imaging analysis. The presence of ground glass opacity (GGO), consolidation and other findings were visually evaluated. CT severity score was calculated according to the extent of lesion involvement. In addition, AI based quantification of GGO and consolidation volume were also performed. 123 patients (mean age: 64.43 ± 14.02; 62 males) were included. GGO + consolidation was more frequently revealed in progress-to-severe group whereas pure GGO was more likely to be found in non-severe group. Compared to non-severe group, patients in progress-to-severe group had larger GGO volume (167.33 ± 167.88 cm versus 101.12 ± 127 cm, p = 0.013) as well as consolidation volume (40.85 ± 60.4 cm versus 6.63 ± 14.91 cm, p < 0.001). Among imaging parameters, consolidation volume had the largest area under curve (AUC) in discriminating non-severe from progress-to-severe group (AUC = 0.796, p < 0.001) and patients with or without critical events (AUC = 0.754, p < 0.001). According to multivariate regression, consolidation volume and age were two strongest predictors for disease progression (hazard ratio: 1.053 and 1.071, p: 0.006 and 0.008) whereas age and diabetes were predictors for unfavorable outcome. Consolidation volume quantified on initial chest CT was the strongest predictor for disease severity progression and larger consolidation volume was associated with unfavorable clinical outcome.

Authors

  • Yuehua Li
    From the Institute of Diagnostic and Interventional Radiology (Y.L., M.Y., X.D., J.Z.) and Department of Cardiology (Z.L., C.S.), Shanghai Jiao Tong University Affiliated Sixth People's Hospital, #600, Yishan Rd, Shanghai, China 200233; Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China (Y.W.); and Department of Radiology, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Centre for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (B.L.).
  • Kai Shang
    Institute of Diagnostic and Interventional Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, #600, Yishan Rd, Shanghai, 200233, China.
  • Wei Bian
    Department of Mathematics, Harbin Institute of Technology, Harbin 150001, China; Institute of Advanced Study in Mathematics, Harbin Institute of Technology, Harbin 150001, China. Electronic address: bianweilvse520@163.com.
  • Li He
    School of Minerals Processing and Bioengineering, Central South University, Changsha 410083, China.
  • Ying Fan
    Division of Clinical Review, Office of Safety and Clinical Evaluation, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
  • Tao Ren
  • Jiayin Zhang
    Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.